Search for stocks /

SMS Pharmaceuticals Q2 FY26 Concall Decoded: PAT Pumps 80%, Backward Integration Pays Off πŸ’Š


1. Opening Hook

When pharma giants blame β€œChina dependence,” SMS Pharma quietly decided to build its own backyard factory. The result? A record-breaking quarter. While others nurse margin blues, SMS turned chemistry into cash flow β€” no lab coat magic, just solid execution.
And if you thought β€œbackward integration” was just corporate jargon, wait till you see how it’s minting margins. Spoiler: this is what happens when your R&D team and your CFO actually talk to each other. Keep reading β€” it gets spicier than Ibuprofen’s price volatility. 😏


2. At a Glance

  • Revenue up 23%: CFO swears it’s demand-driven, not Excel-driven.
  • EBITDA up 54%: Integration works β€” like compound interest, but in chemistry.
  • Margins at 20%: Lab coats and cost controls finally in harmony.
  • PAT up 80%: Best-ever quarter; investors called it β€œpharma steroids.”
  • R&D spend rising: 100 scientists now, planning 200 β€” scientists are the new salesmen.
  • Capex β‚Ή280 Cr: Because expansion is cheaper than excuses.

3. Management’s Key Commentary

Vamsi Potluri: β€œOur PAT grew 80% YoY to β‚Ή25.3 crore β€” the highest ever.”
(Translation: Even the calculator blinked twice before believing this one.)

Vamsi: β€œBackward integration is central to our strategy.”
(Translation: We’re tired of buying intermediates from China β€” now we’re our own supplier.)

Vamsi: β€œInvested β‚Ή150 crore in-house for intermediates, ensuring cost competitiveness.”
(Translation: Spend today, smile tomorrow β€” also sleep better during global supply shocks.)

Vamsi: β€œR&D is our strength; 100 scientists at work, 120 DMFs filed.”
(Translation: Our R&D lab now looks like a crowded coaching class for molecules.)

Vamsi: β€œNew β‚Ή280 crore capex on track; adds capacity and pipeline depth.”
(Translation: Management’s version of saying, β€˜We’re not done flexing yet.’)

Vamsi: β€œExpecting 20% growth and 20% EBITDA margins for FY26.”
(Translation: Double twenties β€” sounds like cricket, but feels like chemistry.) βš—οΈ


4. Numbers Decoded

MetricQ2 FY26YoY GrowthCommentary
Revenueβ‚Ή242.4 Cr+23%Broad-based API demand, especially anti-inflammatory & ARV
Gross Profitβ‚Ή76.8 Cr+30%Integration + stable pricing = sweet chemistry
EBITDAβ‚Ή48.3 Cr+54%Margin hit 20%, CFO smiling visibly
PATβ‚Ή25.3 Cr+80%Best in history, and no one’s complaining
H1 Revenueβ‚Ή438.4 Cr+21%Demand steady across key APIs
Capex Programβ‚Ή280 CrOngoing
Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!